Thousands Sick, Tens of Thousands Suing: Why Trinidad & Tobago Must Act Now on Ozempic and Johnson & Johnson Products
Across the globe, two major product controversies—Ozempic and Johnson & Johnson talc-based powders—are raising urgent red flags about consumer safety. Yet both remain available in Trinidad and Tobago today.
CAIR believes that must be urgently reviewed.
The Numbers Tell the Story
This is not speculation. This is scale.
For Ozempic and similar GLP-1 drugs:
- Nearly 3,000 lawsuits are already consolidated in U.S. federal court over severe gastrointestinal injuries such as stomach paralysis ()
- A second wave of litigation is emerging over vision loss and blindness, with 70+ additional cases already filed across courts ()
For Johnson & Johnson’s talc products:
- The company faces over 67,000 lawsuits from people alleging cancer linked to its products ()
- Some estimates suggest tens of thousands more claims beyond filed cases ()
- Individual jury awards have reached hundreds of millions to over US$1 billion in damages
These are not isolated incidents—they represent mass harm claims on a global scale.
Real People, Real Harm
Behind these numbers are people reporting:
- Stomach paralysis and severe digestive disorders linked to Ozempic
- Permanent vision loss in some GLP-1 drug cases
- Ovarian cancer and mesothelioma linked to long-term talc use
While companies deny liability and maintain their products are safe, courts continue to hear case after case, and new claims continue to emerge.
Why Is Trinidad & Tobago Silent?
Despite these developments:
- These products are still widely available locally
- There have been no major public advisories
- Consumers are largely unaware of the scale of international concern
This creates a dangerous gap between global evidence and local action.
A Call to the Ministry of Health and CFDD
CAIR is calling on the Ministry of Health and the Chemistry Food and Drugs Division to act immediately:
- Launch an urgent safety review of Ozempic and related drugs
- Reassess the safety of talc-based products still on shelves
- Issue public advisories outlining known risks and ongoing litigation
- Consider precautionary restrictions or temporary suspension pending review
When tens of thousands of people are taking legal action worldwide, inaction locally is not neutrality—it is risk.
Precaution Is Not Panic
Let’s be clear: lawsuits are not final proof.
But thousands of lawsuits are a signal.
Public health systems are designed to respond to signals—not wait decades for conclusions while exposure continues.
The Bottom Line
If these products are serious enough to generate:
- 3,000+ injury lawsuits (and growing)
- 67,000+ cancer claims
- billions of dollars in damages awarded
Then they are serious enough to demand immediate scrutiny in Trinidad and Tobago.
Consumers here deserve the same level of protection, transparency, and urgency as anywhere else in the world.
CAIR calls on regulators to act now—before more harm is done.
Contact CAIR today:
.jpg)
Subscribe to our blog and contact CAIR on any of our pages:
